布加综合征的介入放射学管理:中国997例患者10年回顾性多中心调查
该研究回顾性纳入中国6家三级中心2010年1月至2019年5月连续诊断的997例布加综合征患者,评估经皮腔内血管成形术(PTA)联合或不联合常规支架置入及经颈静脉肝内门体分流术(TIPS)的长期结局。中位随访57.3个月,5年总生存率90.2%,TIPS-free生存率83.0%,支架-TIPS-free生存率59.3%,无干预生存率10.6%(P < .001),各BCS亚型结局一致。结论认为以再通为主的介入放射学治疗可使中国BCS患者获得良好长期结局。
要点
- 997例BCS患者中,下腔静脉阻塞占15.7%,肝静脉阻塞占16.2%,混合型占68.1%。
- 834例(83.7%)成功再通,其中PTA alone 566例,PTA联合常规支架268例;90例(9.0%)接受TIPS。
- 中位随访57.3个月,5年总生存率90.2%(95%CI 88.2%-92.3%),TIPS-free生存率83.0%(95%CI 80.5%-85.6%)。
核心结论
- 以再通为主的介入放射学治疗可使中国布加综合征患者获得良好长期结局。
研究设计与样本
- 回顾性、多中心调查,纳入中国6家三级中心2010年1月至2019年5月连续诊断的997例布加综合征患者。
主要发现
- 阻塞类型:下腔静脉15.7%,肝静脉16.2%,混合型68.1%。
- 93.5%表现为中重度症状,60.7%(n=607)病程超过6个月。
- 所有患者接受抗凝治疗;117例(11.7%)仅接受药物治疗,包括65例无症状或轻度症状患者及52例再通失败、不可行或拒绝再通者。
- 834例(83.7%)成功再通,其中PTA alone 566例,PTA联合常规支架268例;90例(9.0%)接受TIPS置入(含46例初始和44例转换手术);无患者接受肝移植。
- 中位随访57.3个月,103例(10.5%)死亡,主要死于肝衰竭;5年总生存率90.2%(95%CI 88.2%-92.3%),TIPS-free生存率83.0%(95%CI 80.5%-85.6%),支架-TIPS-free生存率59.3%(95%CI 56.2%-62.6%),无干预生存率10.6%(95%CI 8.8%-12.7%)(P < .001),各BCS亚型结局一致。
关键数值与推荐
- 5年总生存率90.2%(95%CI 88.2%-92.3%)。
- 5年TIPS-free生存率83.0%(95%CI 80.5%-85.6%)。
- 5年支架-TIPS-free生存率59.3%(95%CI 56.2%-62.6%)。
- 5年无干预生存率10.6%(95%CI 8.8%-12.7%)。
- 以上生存率比较P < .001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Large-scale cohort studies on interventional radiological treatments for Budd-Chiari syndrome (BCS), including percutaneous angioplasty (PTA) with or without routine stenting and transjugular intrahepatic portosystemic shunt (TIPS), are lacking. We aimed to evaluate the long-term outcomes of these treatments in Chinese BCS patients. METHODS: Consecutive patients diagnosed with BCS in 6 Chinese tertiary centers were retrospectively screened for eligibility between January 2010 and May 2019. The roles of the treatment modalities, as well as their associated clinical outcomes, were assessed. RESULTS: Overall, 997 patients were enrolled, with obstruction types classified as inferior vena cava (15.7%), hepatic vein (16.2%), and combined (68.1%). The majority (93.5%) presented with moderate-to-severe symptoms, with 60.7% (n = 607) showing a disease course exceeding 6 months. All patients received anticoagulation, among them, 117 (11.7%) patients underwent medical therapy alone, including 65 asymptomatic or mildly symptomatic patients, and 52 with failed, unfeasible, or declined recanalization; 834 (83.7%) patients successfully recanalized through PTA alone (n = 566) or PTA with routine stenting (n = 268); 90 (9.0%) patients received TIPS placement (comprising 46 initial and 44 converted procedures); and no patients underwent liver transplantation. With a median follow-up of 57.3 months, 103 (10.5%) deaths occurred, primarily from liver failure. The 5-year rates for overall, TIPS-free, stenting-TIPS-free, and intervention-free survival were 90.2% (95% confidence interval [CI]: 88.2%-92.3%), 83.0% (95% CI: 80.5%-85.6%), 59.3% (95% CI: 56.2%-62.6%), and 10.6% (95% CI: 8.8%-12.7%), respectively (P < .001), with consistent outcomes across BCS subtypes. CONCLUSIONS: With predominantly inferior vena cava obstruction presented and recanalization used, interventional radiological treatment could achieve a good long-term outcome in Chinese patients with BCS.
引用
- Xia D, Luo B, Zhang C, et al. Interventional Radiological Management for Budd-Chiari Syndrome: A 10-Year Retrospective, Multicenter Survey on 997 Patients in China. Clin Gastroenterol Hepatol. 2025. PMID: 40669576. doi:10.1016/j.cgh.2025.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。